You are here » Home » Markets » Stocks » Announcements

ANNOUNCEMENTS

Announcement for "Ajanta Pharma Ltd"

Ajanta Pharma Ltd Updates

  • 25/11/2016
  • |
  • bse

Ajanta Pharma Ltd Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

  • 21/11/2016
  • |
  • bse

Ajanta Pharma Ltd Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011

  • 21/11/2016
  • |
  • bse

Ajanta Pharma Ltd Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

  • 21/11/2016
  • |
  • bse

Ajanta Pharma Ltd Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011

  • 21/11/2016
  • |
  • bse

Ajanta Pharma Ltd Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulation

  • 10/11/2016
  • |
  • bse

Ajanta Pharma Ltd Ajanta Pharma Announces Approval & Launch of Amlodipine + Olmesartan Medoxomil Tablets in US Market

  • 02/11/2016
  • |
  • bse

Ajanta Pharma Ltd Dividend Payment Date

  • 27/10/2016
  • |
  • bse

Ajanta Pharma Ltd Investor Presentation

  • 26/10/2016
  • |
  • bse

Ajanta Pharma Ltd Fixes Record Date for Interim Dividend

  • 26/10/2016
  • |
  • bse

Ajanta Pharma Ltd Board declares Interim Dividend

  • 26/10/2016
  • |
  • bse

Ajanta Pharma Ltd Announces Q2 results (Standalone & Consolidated) Limited Review Report (Standalone & Consolidated) &

  • 26/10/2016
  • |
  • bse

Ajanta Pharma Ltd Closure of Trading Window

  • 14/10/2016
  • |
  • bse

Ajanta Pharma Ltd Q2 results on Oct 26 2016

  • 14/10/2016
  • |
  • bse

Ajanta Pharma Ltd Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations 2015 for Quarter ended S

  • 13/10/2016
  • |
  • bse

Ajanta Pharma Ltd Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011

  • 28/09/2016
  • |
  • bse

Ajanta Pharma Ltd Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011

  • 26/09/2016
  • |
  • bse

Ajanta Pharma Ltd Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011

  • 24/09/2016
  • |
  • bse

Ajanta Pharma Ltd Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011

  • 24/09/2016
  • |
  • bse

Ajanta Pharma Ltd Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

  • 24/09/2016
  • |
  • bse

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard